Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
Novo Nordisk will conduct a non-exclusive internal evaluation of semaglutide implants prepared by VivaniALAMEDA, Calif., July 07, 2026 (GLOBE NEWSWIRE
